Tarceva erlotinib regulatory update

OSIP said its NDA for Tarceva to treat advanced or metastatic non-small cell lung cancer (NSCLC) was accepted into FDA's Pilot 1 Program for Continuous Marketing Applications (CMAs). The program allow...